Kevin Boyle Senior: Right. Thanks, Yale. Yes. Indeed, the patient number three will be at the second dose level. That’s where we intend to treat the patient. As you are aware, there is a range for the dose levels and so the dose Level 2 is anywhere from approximately 10 billion TCR-T cells to 70 TCR-T — 70 billion TCR-T cells. And so though we are not communicating on the exact number in that range, we would anticipate and that’s really the guidance of the treating physician where the dose level is.
Yale Jen: Okay. Great. That’s very helpful. One more question here is that the in terms of the two added new TCR-T, I didn’t get it quite clearly, could you just repeat what specifically those are the configuration of that dose two.
Drew Deniger: Yeah. Thanks, Yale. This is Drew here. We are very excited to add these new TCRs into the library. As part of the IND amendment that we are filing we haven’t gotten clearance from the FDA for that those TCRs just yet. So we haven’t announced the specific identity something, but we will once they have been clear and we anticipate that they will be cleared, because we have already expanded the library from six to 10 late last year. So that’s our expectation, but we don’t want to be presumptuous with the FDA, so taking a bit of caution here. We can say that we do think it’s going to make a significant increase in the number of patients that can be enrolled in the trial and that we can bring TCR-T cell therapy to as we move forward.
Yale Jen: Okay. Great. That’s very helpful. Maybe the last just housekeeping question here, in terms of this quarter, you have $2.9 million revenues from Solasia Pharma. Do we anticipate this being — this to be a one-time event or it could occur periodically going forward? And thanks.
Kevin Boyle Senior: Mike, do you want to take that?
Mike Wong: Sure. Thanks, Yale. We are definitely very pleased on the regulatory approval and the achievement of first commercial sale of darinaparsin in Japan and this was first non-dilutive funding for the company. We anticipate the upfront payment that we received from Solasia in the third quarter of 2022 will be the most meaningful payment that we will receive over the next few years.
Yale Jen: Okay. Great. That’s very helpful and congrats on the progress.
Kevin Boyle Senior: Thank you.
Drew Deniger: Thanks, Yale.
Operator: Our next question comes from the line of Thomas Flaten with Lake Street Capital Markets. Your line is now open.
Thomas Flaten: Very thanks for taking the question. Drew, just back to the TCRs, I am assuming it’s safe to assume that there within the three genes that you guys are already focused on, right?
Drew Deniger: Yeah. That is correct, Thomas. It will be within KRAS, TPP53 or EGFR, and again, to reiterate that we are looking to add more mutations within the existing genes and to add more HLAs within the existing mutations. So it’s consistent with that thesis it will be along those same lines.
Thomas Flaten: Got it. And going back to the first question about enrollment pacing, if you look at the time that the lapse since patient number two enrolled, has it been availability of patients, was there a manufacturing that kind of stood in the way of another patient enrolling sooner? I am just trying to get some more insight into that time frame that has elapsed?